Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bristol Myers Squibb
Bristol Myers Squibb
Bristol Myers Squibb bids farewell to dealmaking czar Elizabeth Mily
Fierce Pharma
Sun, 12/10/23 - 11:03 pm
Bristol Myers Squibb
M&A
Elizabeth Mily
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
BioSpace
Fri, 12/8/23 - 10:00 am
Bristol Myers Squibb
Opdivo
Yervoy
colorectal cancer
metastatic colorectal cancer
clinical trials
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Tue, 12/5/23 - 11:53 pm
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
BMS, Avidity add another link to cardiovascular partnership with $100M expansion
Fierce Biotech
Tue, 11/28/23 - 10:29 am
Bristol Myers Squibb
Avidity Biosciences
R&D
cardiovascular disease
FDA to delay decision on Bristol Myers-2seventy bio cancer therapy
Reuters
Mon, 11/20/23 - 10:12 am
Bristol Myers Squibb
2seventy bio
blood cancer
FDA
Abecma
BMS gets US approval for ROS1 lung cancer drug Augtyro
Pharmaphorum
Thu, 11/16/23 - 10:11 am
Bristol Myers Squibb
Augtyro
Turning Point Therapeutics
lung cancer
FDA
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Motley Fool
Sun, 11/12/23 - 09:30 pm
Merck
Bristol Myers Squibb
antibody-drug conjugate
Bristol Myers pays $100M for a different kind of ADC
BioPharma Dive
Mon, 11/6/23 - 09:54 am
Bristol Myers Squibb
antibody-drug conjugate
bone cancer
blood cancer
Orum Therapeutics
Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway
BioSpace
Sun, 10/29/23 - 08:53 pm
earnings
Bristol Myers Squibb
Takeda
Novartis
Sanofi
Merck
Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow
Zacks.com
Thu, 10/26/23 - 10:58 pm
Bristol Myers Squibb
earnings
Bristol Myers says it needs another year to hit target for new drugs
Reuters
Thu, 10/26/23 - 10:40 am
Bristol Myers Squibb
Reblozyl
Sotyktu
Zeposia
BMS buys Asian rights to key growth drug Camzyos
Pharmaphorum
Wed, 10/25/23 - 09:46 am
Bristol Myers Squibb
Asia
Camzyos
obstructive hypertrophic cardiomyopathy
Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO
BioSpace
Mon, 10/23/23 - 05:15 pm
ESMO
Merck
Bristol Myers Squibb
bladder cancer
PD-1 inhibitors
Keytruda
Padcev
Opdivo
ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow
Fierce Pharma
Sun, 10/22/23 - 06:06 pm
ESMO
Bristol Myers Squibb
Opdivo
bladder cancer
Padcev
Keytruda
Merck
BMS, Halozyme score with subcutaneous version of Opdivo
Fierce Pharma
Thu, 10/19/23 - 10:42 pm
Bristol Myers Squibb
Halozyme
Opdivo
clinical trials
Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod
Fierce Pharma
Mon, 10/16/23 - 11:45 am
Bristol Myers Squibb
Opdivo
melanoma
FDA
Pfizer takes aim at BMS' first-in-class Zeposia with FDA nod for ulcerative colitis drug Velsipity
Fierce Pharma
Fri, 10/13/23 - 10:35 am
Bristol Myers Squibb
Zeposia
Pfizer
Velsipity
etrasimod
ulcerative colitis
FDA
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
CP Wire/Businesswire
Sun, 10/8/23 - 06:16 pm
Bristol Myers Squibb
M&A
Mirati Therapeutics
oncology
cancer
Krazati
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Tue, 10/10/23 - 05:29 pm
Bristol Myers Squibb
M&A
Mirati Therapeutics
oncology
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
Drugs.com
Sun, 10/8/23 - 02:38 pm
Paradigm Health
Bristol Myers Squibb
clinical trials
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »